Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lorlatinib
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Lorlatinib is a third-generation small molecule tyrosine kinase inhibitor developed for the treatment of non-small cell lung cancer (NSCLC) that harbors genetic alterations in the anaplastic lymphoma kinase (ALK) gene or ROS1 gene. It works by selectively inhibiting ALK and ROS1 kinases, including many mutated forms that confer resistance to earlier ALK inhibitors. Lorlatinib is notable for its ability to cross the blood-brain barrier, making it effective against brain metastases in NSCLC patients. The drug was developed and is manufactured by Pfizer. It received initial FDA approval in 2018 for use in patients with metastatic ALK-positive NSCLC who have progressed on prior ALK inhibitors.
- Brand names
- LorbrenaLorviqua
- Other names
- lorlatinibPF-06463922PF06463922PF 06463922
02
Targets
TNK2 (Activated Cdc42-associated kinase 1)ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)FAK (Focal adhesion kinase)PTK2BFER (FER tyrosine kinase)FES (Proto-oncogene tyrosine-protein kinase Fes)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)NTRK1 (Tropomyosin-related receptor kinase A)NTRK2 (Tropomyosin-related kinase receptor type B)NTRK3 (Tropomyosin receptor kinase C)LTK (Leukocyte receptor tyrosine kinase)
Beyond the preview
Go deeper on lorlatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lorlatinib.